Ignite Creation Date:
2024-05-05 @ 12:05 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00243152
Status:
COMPLETED
Last Update Posted:
2018-12-07
First Post:
2005-10-19
Brief Title:
Evaluation of Lamotrigine on Neuropathic Facial Pain Using fMRI
Sponsor:
Pain and Analgesia Imaging and Neuroscience Group
Organization:
Pain and Analgesia Imaging and Neuroscience Group
Study Overview
Official Title:
Evaluation of Lamotrigine on Neuropathic Facial Pain Using fMRI
Status:
COMPLETED
Status Verified Date:
2018-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of this project is to evaluate the effects of the anticonvulsant drug lamotrigine trade name Lamictal on neuropathic facial pain or neuralgia using functional magnetic resonance imaging fMRI
Detailed Description:
Currently there are no pharmacological agents that can control neuropathic pain akin to the efficacy of antibiotics for bacterial infection All current neuropathic pain drugs have approximately the same efficacy of less than 30 in controlled trials and many of these drugs do not have known mechanisms of action fMRI studies may provide insight into how brain circuitry is altered by chronic pain and how these drugs act on altered circuitry The trigeminal system in particular offers unique advantages for studying such alterations including a large central representation and high degree of somatotopy The administration of lamotrigine to neuropathic pain patients in conjunction with fMRI will allow us to compare subjective ratings of pain with objective measures of neural activity during increased conditions of allodyniahyperalgesia
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None